# Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

> **NCT02606305** · PHASE1,PHASE2 · COMPLETED · sponsor: **ImmunoGen, Inc.** · enrollment: 264 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Mirvetuximab soravtansine
- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Pegylated Liposomal Doxorubicin
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02606305
- **Lead sponsor:** ImmunoGen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-02
- **Primary completion:** 2021-03-12
- **Final completion:** 2021-03-12
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02606305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02606305, "Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02606305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*